Qiagen agreed to acquire single‑cell specialist Parse Biosciences for up to $280 million, signaling continued consolidation as large instrument companies absorb high‑throughput single‑cell technologies. Parse founders will remain in leadership as Qiagen integrates the GigaLab and Parse workflows. The deal arrives as 10x Genomics reported a year‑over‑year dip in Q3 instrument revenues and modest consumables growth, illustrating pressure on standalone single‑cell incumbents and a shift toward platform consolidation that could reshape customer choice, support models and innovation pacing in single‑cell and spatial biology.